Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Health Care · CIK 0000310764
$307.08
+3.19% · delayed ~15 min
Last price from Oct 22, 2026
$117.18B market value
From STRYKER CORP's FY2025 10-K, filed Feb 11, 2026 · read the filing
STRYKER makes medical devices and equipment. It took in $25.12B last year, which makes it a large company. Of every dollar it sells, about 13 cents is left as profit.
The financial picture is led by profitability, debt and accounting, with growth worth watching.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Recent open-market selling by 3 insiders, not under a pre-arranged plan.
$118.2M sold in the last 120 days · Read the filing
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
Strong finances across the board.
From STRYKER CORP's FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Operating income
$3.69B → $4.89B
Operating margin
16.3% → 19.5%
Free cash flow
$3.49B → $4.28B
Long-term debt
$12.19B → $14.86B
Measured against FY2024, from the 10-K filed Feb 11, 2026
Improved: +32.5%
$3.69B to $4.89BSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
How the latest move compares (quote delayed ~15 min), and what was published around it
SYK rose 3.19% on the latest quote. The average Health Care company tracked here moved +1.58%, and the S&P 500 −1.04%. That is 1.6 points above its sector and 4.2 points above the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 11% a year for the next 10 years. Over the last 10 years it grew by about 20% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 13 cents of every dollar of sales as profit, earning $3.25B last year.
Slowly. Sales grew 11.2% last year.
No. At its current cash flow it could clear its debt in about 2.3 years. For every $1 it owes, it owns $1.88 in assets.
Core operating and valuation reference metrics
Whether the dividend is covered by what the business actually earns
It pays out 40 cents of every dollar of profit and keeps the rest, which leaves the payment comfortably covered. It paid out 25% of the cash its operations generated. It has paid in each of the last 12 years.
GoodNext payment expected around , projected from how regularly it has paid before rather than from a date the company has announced.
Figures from the FY2025 annual filing
Last year it earned $3.25B and generated $5.04B of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 11, 2026Filing for FY2025 | FY202410-K · Feb 12, 2025Filing for FY2024 | FY202310-K · Feb 12, 2025Filing for FY2023 | FY202210-K · Feb 12, 2025Filing for FY2022 | FY202110-K · Feb 11, 2022Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $25.12B | $22.59B | $20.50B | $18.45B | $17.11B | +11.2% |
| Cost of revenue | $9.05B | $8.15B | $7.44B | $6.87B | $6.14B | +11.0% |
| Gross profit | $16.07B | $14.44B | $13.06B | $11.58B | $10.97B | +11.3% |
| Gross marginGross profit ÷ revenueWhat is this? | 64.0% | 63.9% | 63.7% | 62.8% | 64.1% | +0.1 pts |
| Selling, general and administrative | $8.65B | $7.68B | $7.11B | $6.39B | $6.43B | +12.6% |
| Operating income | $4.89B | $3.69B | $3.89B | $2.84B | $2.58B | +32.5% |
| Operating marginOperating income ÷ revenueWhat is this? | 19.5% | 16.3% | 19.0% | 15.4% | 15.1% | +3.1 pts |
| Interest expense | $582.0M | $396.0M | $356.0M | $337.0M | $337.0M | +47.0% |
| Income before tax | $4.51B | $3.49B | $3.67B | $2.68B | $2.28B | +29.3% |
| Net income | $3.25B | $2.99B | $3.17B | $2.36B | $1.99B | +8.5% |
| Net marginNet income ÷ revenueWhat is this? | 12.9% | 13.2% | 15.4% | 12.8% | 11.7% | −0.3 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $8.51 | $7.87 | $8.35 | $6.25 | $5.30 | +8.1% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| SYKSTRYKER CORP · this page | 9.0/10 | 6/9 |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Reported another kind of transaction — 109 shares
Holds 3,661 shares after this filing.
Reported another kind of transaction — 1,777 shares
Holds 4,732 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Had a director or senior officer leave or join · Made a Regulation FD disclosure
Read the filingQuarterly report for Q2 FY2026
Revenue +9.4% · Operating margin +6.7 pts · Operating income +49.1% — against Q2 FY2025
Read the filingWrite down why you are following STRYKER CORP, what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 191 subsidiaries named in its 10-K, incorporated across 54 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from SYK's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 11, 2026), reported under the US GAAP taxonomy. View the source filing.
4 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. All four had enough reported figures. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 9.0 | 6/9 | 10-K, filed Feb 11, 2026 |
| FY2024 | 9.0 | 7/9 | 10-K, filed Feb 12, 2025 |
| FY2023 | 9.0 | 8/9 | 10-K, filed Feb 14, 2024 |
| FY2022 | 8.0 | 7/9 | 10-K, filed Feb 10, 2023 |
| FY2021 | 10.0 | 9/9 | 10-K, filed Feb 11, 2022 |
| FY2020 | 7.0 | 4/9 | 10-K, filed Feb 11, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
6 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
4.40
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.62
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: +3.1 pts
16.3% to 19.5%Significant
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +22.8%
$3.49B to $4.28BSignificant
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Deteriorated: +21.9%
$12.19B to $14.86BSignificant
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Improved: +11.2%
$22.59B to $25.12BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +11.3%
$14.44B to $16.07BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +8.5%
$2.99B to $3.25BNotable
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +8.1%
$7.87 to $8.51Notable
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +9.8%
$3.65B to $4.01BNotable
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Changed: +5.3%
$1.22B to $1.28BNotable
Why it matters: Cash handed to shareholders. A rise can be a higher dividend or simply more shares, and a cut is a decision the company explains in its own filing — neither is rated here.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Jul 31, 2026 — read it.
Improved: +49.1%
$1.11B to $1.66BCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +44.3%
$884.0M to $1.28BCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +43.9%
$2.31 to $3.33Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +42.8%
$2.38B to $3.39BCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +17.1%
$3.84B to $4.50BSignificant
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +4.5 pts
63.8% to 68.3%Significant
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Improved: +6.7 pts
18.5% to 25.2%Significant
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +4.7 pts
14.7% to 19.4%Significant
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: +9.4%
$6.02B to $6.59BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Jul 31, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Improved: +77.2%
$936.0M to $1.66BCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +71.3%
$745.0M to $1.28BCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +9.6 pts
15.5% to 25.2%Critical
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +71.2%
$1.94 to $3.33Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +18.1%
$3.81B to $4.50BSignificant
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +5.0 pts
63.3% to 68.3%Significant
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Improved: +7.0 pts
12.4% to 19.4%Significant
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: +17.8%
$2.88B to $3.39BSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +9.5%
$6.02B to $6.59BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
4 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 9% and 13%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Opinions from 33 analysts covering this company, as of . Their views, not this site's.
Of 33 analysts publishing on this company, 12 say strong buy, 15 say buy and 6 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 1.5% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 31.1x — a high multiple relative to the current trailing profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
| 11.2% |
| 12.9% |
| 36.10x |
| 1.13x |
| ABTABBOTT LABORATORIES | 9.0/10 | 6/9 | 5.7% | 14.7% | 27.25x | 0.66x |
|---|
| ISRGINTUITIVE SURGICAL INC | 10.0/10 | 7/8 | 20.5% | 28.4% | 55.19x | 0.14x |
|---|
| BSXBOSTON SCIENTIFIC CORP | 10.0/10 | 8/9 | 19.9% | 14.4% | 23.48x | 0.80x |
|---|
| BDXBECTON DICKINSON & CO | 7.0/10 | 6/9 | 8.2% | 7.7% | 34.09x | 1.18x |
|---|
| EWEdwards Lifesciences Corp | 9.0/10 | 6/9 | 11.5% | 17.7% | 48.73x | 0.32x |
|---|
| IDXXIDEXX LABORATORIES INC /DE | 9.0/10 | 8/9 | 10.4% | 24.6% | 42.64x | 1.09x |
|---|
| RMDRESMED INC | 9.0/10 | 8/9 | 9.9% | 26.9% | 23.96x | 0.36x |
|---|
| DXCMDEXCOM INC | 8.7/10 | 7/8 | 15.6% | 17.9% | 36.04x | 1.31x |
|---|
| Median of peers | 9.0/10 | — | 11.0% | 17.8% | 35.06x | 0.73x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Reported another kind of transaction — 962 shares
Holds 3,770 shares after this filing.
Bought on the open market — 63 shares at $202.21 ($12.7K)
Holds 63 shares after this filing.
Bought on the open market — 11 shares at $221.03 ($2.4K)
Holds 0 shares after this filing.
Bought on the open market — 36 shares at $193.21 ($7.0K)
Holds 99 shares after this filing.
Bought on the open market — 3 shares at $185.65 ($556.95)
Holds 102 shares after this filing.
Bought on the open market — 18 shares at $225.19 ($4.1K)
Holds 131 shares after this filing.
Sold on the open market — 441 shares at $328.61 ($144.9K)
Holds 6,102 shares after this filing.
Sold on the open market — 2,239 shares at $331.74 ($742.8K)
Holds 2,599,136 shares after this filing.
Sold on the open market — 2,920 shares at $332.69 ($971.5K)
Holds 2,596,216 shares after this filing.
Sold on the open market — 8,404 shares at $333.82 ($2.8M)
Holds 2,587,812 shares after this filing.
Sold on the open market — 25,536 shares at $334.94 ($8.6M)
Holds 2,562,276 shares after this filing.
Sold on the open market — 131,752 shares at $335.64 ($44.2M)
Holds 2,430,524 shares after this filing.
Sold on the open market — 109,425 shares at $336.43 ($36.8M)
Holds 2,321,099 shares after this filing.
Sold on the open market — 16,243 shares at $337.63 ($5.5M)
Holds 2,304,856 shares after this filing.
Sold on the open market — 3,481 shares at $338.50 ($1.2M)
Holds 2,301,375 shares after this filing.
Sold on the open market — 40 shares at $331.81 ($13.3K)
Holds 2,301,335 shares after this filing.
Sold on the open market — 440 shares at $333.18 ($146.6K)
Holds 2,300,895 shares after this filing.
Sold on the open market — 200 shares at $333.93 ($66.8K)
Holds 2,300,695 shares after this filing.
Sold on the open market — 80 shares at $335.06 ($26.8K)
Holds 2,300,615 shares after this filing.
Sold on the open market — 320 shares at $336.79 ($107.8K)
Holds 2,300,295 shares after this filing.
Sold on the open market — 2,308 shares at $337.98 ($780.1K)
Holds 2,297,987 shares after this filing.
Sold on the open market — 11,257 shares at $338.90 ($3.8M)
Holds 2,286,730 shares after this filing.
Sold on the open market — 10,812 shares at $339.71 ($3.7M)
Holds 2,275,918 shares after this filing.
Sold on the open market — 16,612 shares at $340.71 ($5.7M)
Holds 2,259,306 shares after this filing.
Sold on the open market — 3,274 shares at $341.84 ($1.1M)
Holds 2,256,032 shares after this filing.
Sold on the open market — 3,852 shares at $342.80 ($1.3M)
Holds 2,252,180 shares after this filing.
Sold on the open market — 805 shares at $343.47 ($276.5K)
Holds 2,251,375 shares after this filing.
Sold on the open market — 826 shares at $336.30 ($277.8K)
Holds 6,210 shares after this filing.
Had shares withheld to cover taxes — 155 shares at $325.70 ($50.5K)
Holds 1,717 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 826 shares ($277.8K) on or after .
Shares originally obtained via RSU Vesting.
Filed notice to sell 350,000 shares ($117.3M) on or after .
Shares originally obtained via Estate Division.
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Published results
Reported another event
Read the filingHad a director or senior officer leave or join
Read the filingQuarterly report for Q1 FY2026
Operating margin +1.3 pts · Free cash flow +226.8% · Cash +24.1% — against Q1 FY2025
Read the filingHeld a shareholder vote
Read the filingPublished results
Read the filingDisclosed a material cybersecurity incident · Made a Regulation FD disclosure
Read the filingProxy statement for a shareholder meeting
Read the filingMade a Regulation FD disclosure
Read the filingMade a Regulation FD disclosure
Read the filingReported another event
Read the filingAnnual report for FY2025
Revenue +11.2% · Operating margin +3.1 pts · Operating income +32.5% — against FY2024
Read the filingPublished results
Read the filingHad a director or senior officer leave or join · Made a Regulation FD disclosure
Read the filingQuarterly report for Q3 FY2025
Revenue +10.2% · Operating margin −1.0 pts · Cash -15.4% — against Q3 FY2024
Read the filingPublished results
Read the filingQuarterly report for Q2 FY2025
Revenue +11.1% · Long-term debt +46.4% · Cash +26.7% — against Q2 FY2024
Read the filingPublished results
Read the filingThe first 40 of 191. The rest are in the exhibit.
Source: Exhibit 21 of the 10-K filed 2026-02-11. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
Stryker (SYK) Stock May Trade At A Discount Despite FDA Clearance
Yahoo Finance ·
Global Laparoscope Market Size, Share, Trends, and Forecast for Rigid and Flexible Scopes, 2026-2032 | 4K, 3D, and Integrated Systems Fuel 6.3% CAGR to $1.3 Billion
Yahoo Finance ·
Stryker (SYK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Yahoo Finance ·
PAHC or SYK: Which Is the Better Value Stock Right Now?
Yahoo Finance ·
Stryker's Sonopet 3 Secures FDA Clearance to Improve Surgical Accuracy
Yahoo Finance ·
Is Stryker Corp. (SYK) Positioned for Above-Market Growth?
Yahoo Finance ·
2 Dividend Stocks to Buy and Hold Forever
Yahoo Finance ·
Intuitive Surgical (ISRG): Does Leasing Make Growth More Durable or More Capital Intensive?
Yahoo Finance ·
The Zacks Analyst Blog Highlights Abbott Laboratories, Johnson & Johnson, Stryker, Waste Management and Republic Services
Yahoo Finance ·
Can Boston Scientific Stock Jump 30%?
Yahoo Finance ·
How Has Intuitive Surgical's Story Changed?
Yahoo Finance ·
Can Boston Scientific Stock Bounce Off This Support Again?
Yahoo Finance ·
Primary sources and further research